A secondary objective was objective response by RECIST v1.1 per investigator assessment.Among 110 evaluable patients (arm A, n=22; arm B, n=50; arm C, n=38), median age was 58.0 (range, 3579) years and 50% had received 1 or 2 prior lines of therapy. DLTs occurred in 19 patients ...
Its increasing popularity is reflected by a steadily rising impact factor.doi:10.1038/bjc.2013.809G ChangJ WangH ZhangY ZhangC WangH XuY LinL MaQ LiT PangBritish Journal of Cancer
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumorsdoi:10.1007/s10637-022-01326-3Stathis, AnastasiosTolcher, Anthony W.Wang, Judy S....
ERK inhibitorMEK inhibitorMK-8353SelumetinibSolid tumorsTolerabilityAim: We evaluated MK-8353 (small molecule inhibitor of extracellular signal-regulated kinase 1/2) plus selumetinib (mitogen-activated extracellular signal-regulated kinase 1/2 inhibitor) in patients with advanced solid tumors. Methods: ...
The significance of Chlamydia trachomatis in prostatitis syndrome Journal of Chemotherapy Vol 26, No 6Miram PasiniViktor KotarskiVedrana ŠkerkAlemka MarkotićArjana Tambić AndraševićSnježana Židovec LepejGordan MalekovićSunčanica Ljubin Sternak...